Search Results
Your search for ,wAS matches 27442 pages
Showing 13551 - 13600NCCN Summit Tackles Inequities in Access to Care
WHEN BRANDON CANYON’S mother Leone was diagnosed with uterine cancer, he drove her to treatment sessions at the nearest cancer center—a 200-mile round trip on rough roads. Gas was a significant expense, but their only other option was to forgo treatment. The Canyons are members of the Navajo...
American Society of Breast Surgeons Recommends Genetic Testing for Newly Diagnosed Patients With Breast Cancer
IN A MOVE that is a significant departure from current testing recommendations, the American Society of Breast Surgeons (ASBrS) recommends that genetic testing be available to all individuals newly diagnosed with breast cancer.1 The new recommendations expand on common restrictions by the National...
Expert Point of View: Jason Luke, MD, FACP
DISCUSSANT OF the abstract presented by Pinato et al, Jason Luke, MD, FACP, Assistant Professor of Medicine at the University of Chicago Comprehensive Cancer Center, called the survival difference for patients receiving antibiotics prior to checkpoint blockade “rather dramatic and quite...
Antibiotic Treatment Prior to Immune Checkpoint Inhibitor Therapy Shows Detrimental Effect on Response and Survival
USE OF ANTIBIOTICS prior to checkpoint blockade therapy may attenuate anticancer activity, according to data presented at the 2019 ASCO–Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium.1 Results of the multicenter study suggest that antibiotic therapy administered...
PARP Inhibitors Moving Ahead in Prostate Cancer
MULTIPLE POLY (ADP-ribose) polymerase (PARP) inhibitors are under study in metastatic prostate cancer and no clear winner has emerged yet. Some studies suggest that the best use of PARP inhibitors may be in patients whose cancers harbor DNA-repair defects and BRCA1/2 mutations, but other data...
Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
ON DECEMBER 14, 2018, trastuzumab-pkrb (Herzuma) was approved as a biosimilar to trastuzumab for patients with HER2-overexpressing breast cancer.1 Trastuzumab-pkrb is indicated for adjuvant treatment of HER2-overexpressing breast cancer and metastatic HER2-overexpressing breast cancer.2 Health-care ...
Erratum
In the March 10, 2019, issue of The ASCO Post, a photo on page 10, in the article, “ARAMIS Trial Reports Darolutamide Improves Outcomes in High-Risk Nonmetastatic Prostate Cancer,” was incorrectly identified as Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Université Paris-Sud, Villejuif, ...
Antibody-Drug Conjugate Shows Activity in Heavily Pretreated Bladder Cancer
PRELIMINARY EVIDENCE suggests that the antibody-drug conjugate sacituzumab govitecan is active in patients previously treated with chemotherapy or checkpoint inhibitor therapy for metastatic urothelial cancer. These results from a phase I/II basket study of this agent were presented at the 2019...
New Data in Colorectal, Neuroendocrine, Gastric, and Hepatocellular Cancers
THE ANNUAL GASTROINTESTINAL CANCERS SYMPOSIUM took place earlier this year in San Francisco. In addition to important studies captured in our past few issues, The ASCO Post here briefly summarizes additional interesting studies. Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Colon Cancer...
Caring: Isn’t That Why We Went to Medical School?
YOU CANNOT write about caring; you must practice it. None of us went to medical school thinking we would be an oncologist or a neurosurgeon or a stem cell biologist. But we did have vague aspirations of wanting to help others: to be involved in other lives. It was an altruistic avocation; how...
Expert Point of View: Siwen Hu-Lieskovan, MD, PhD
DISCUSSANT OF the CheckMate 384 trial, Siwen Hu-Lieskovan, MD, PhD, Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah, called the short-term safety data “convincing.” However, she noted that the long-term impact of intermittent, lower-minimum concentration...
CheckMate 384 Supports More Convenient Dosing of Nivolumab in Advanced NSCLC
PATIENTS WITH advanced non–small cell lung cancer (NSCLC) may no longer have to come to the clinic every 2 weeks for treatment. According to a descriptive analysis of the phase IIIb/IV CheckMate 384 study, a more convenient dosing option of nivolumab has demonstrated convincing short-term safety...
Addition of Docetaxel to Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Rosenthal et al, the phase III NRG Oncology RTOG 0521 trial showed that the addition of docetaxel to androgen suppression and radiotherapy improved overall and disease-free survival as well as the distant metastasis rate in patients with high-risk...
Focal Laser Ablation in Prostate Cancer
Researchers have shown that selectively destroying cancerous prostate tissue may be as effective as complete prostate removal or radiation therapy, while preserving more sexual and urinary function than these other treatments. The study was published by Wasler et al in the Journal of Vascular and...
Breast Density Assessment Variation by Screening Modality
Fewer women are assigned to a dense-breast category when evaluated with advanced mammographic screening technologies compared to standard digital mammography, according to a new study published by Gastounioti et al in Radiology. Density Assessment A woman’s breast density is assessed during ...
Ultradeep Next-Generation Sequencing in Patients With Lung Cancer
A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from patients with lung cancer with a high degree of accuracy, according research published by Li et al in Annals of Oncology. Liquid Biopsies and...
Genomic Testing Associated With Lower Health-Care Costs in Patients With High-Risk Breast Cancer
New research published by Dinan et al in JNCCN—Journal of the National Comprehensive Cancer Network provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast...
Pachymeningeal Seeding After Neurosurgical Resection in Patients With Brain Metastases
In a retrospective cohort study reported in JAMA Oncology, Cagney et al found that pachymeningeal seeding was fairly common after neurosurgical resection in patients with brain metastases treated with adjuvant stereotactic radiation. Study Details The study involved 1,188 consecutive patients...
Pertuzumab Plus Trastuzumab in HER2-Amplified Metastatic Colorectal Cancer
As reported in The Lancet Oncology by Meric-Bernstam et al, the combination of pertuzumab and trastuzumab showed activity in HER2-amplified metastatic colorectal cancer in the phase IIa multiple basket study MyPathway. The study is evaluating activity of targeted therapies in nonindicated tumor...
Artificial Intelligence vs Radiologists in Breast Cancer Detection With Digital Mammography
In a study reported in the Journal of the National Cancer Institute, Rodriguez-Ruiz et al found that a stand-alone artificial intelligence (AI) system had accuracy comparable to an average breast radiologist in detecting breast cancer using digital mammography. Study Details In the retrospective...
Therapy-Related Cardiac Disease Risk in Childhood Cancer Survivors
As reported by Bates et al in the Journal of Clinical Oncology, an analysis from the Childhood Cancer Survivor Study indicated that radiation doses in conjunction with heart volume exposed to radiation and anthracycline treatment were associated with increased risk of late-onset cardiac disease in...
FDA Pipeline: Safety Warning About Investigational Use of Venetoclax in Multiple Myeloma, Warning Letter on Unapproved Products
This week, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma, and also posted a warning letter against a company for illegally marketing unapproved products labeled as homeopathic. Safety Statement The FDA posted...
Does Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer Decrease the Risk of Surgical Complications?
In a Danish study reported in JAMA Surgery, Jørgensen et al found that the nationwide introduction of minimally invasive robotic surgery for early-stage endometrial cancer was associated with a reduction in the incidence of severe complications. The nationwide prospective cohort study...
Effect of Microsatellite Instability and Tumor Mutational Burden on Outcome in First-Line Treatment of Metastatic Colorectal Cancer
In an analysis of the phase III CALGB/SWOG 80405 trial reported in the Journal of Clinical Oncology, Innocenti et al found that tumor mutational burden and microsatellite instability status affected overall survival in patients receiving first-line chemotherapy plus bevacizumab or cetuximab for...
Validation Study of Several Models of Breast Cancer Risk
In a validation study reported in The Lancet Oncology, Terry et al found that the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA) and the International Breast Cancer Intervention Study model (IBIS) were the best of 4 models tested for predicting...
Persistent Long-Term Fatigue and Impact on Quality of Life Among Epithelial Ovarian Cancer Survivors
A study among epithelial ovarian cancer survivors from 25 cooperative Gynecologic Cancer Intergroup centers in France showed similar quality of life compared to healthy controls who were randomly selected from the electoral rolls, but persistent long-term fatigue. The researchers found depression,...
Infertility in Women and Low Absolute Risk of Cancer
A study of over 64,000 women of childbearing age in the United States has found that infertility is associated with a higher risk of developing cancer compared to a group of over 3 million women without fertility problems—although the absolute risk is very low, at just 2%. These findings ...
AR-V7 Assay Findings and Outcomes With Hormone Therapy in High-Risk Castration-Resistant Prostate Cancer
In the PROPHECY study, reported in the Journal of Clinical Oncology, Armstrong et al found that positive findings on 2 assays for circulating tumor cell (CTC) androgen receptor splice variant 7 (AR-V7) were associated with poorer outcomes for abiraterone and enzalutamide therapy in men with...
Effect of Medical Cannabis on Symptom Control in Patients With Cancer
As reported in the Journal of Oncology Practice by Anderson et al, a study of patients enrolled in Minnesota’s Medical Cannabis Program showed that the use of medical cannabis was associated with improvement in reported symptoms in patients with cancer. The study involved data on 1,120...
Neratinib Plus Capecitabine Active Against HER2-Positive Breast Cancer Brain Metastases
In the phase II TBCRC 022 trial reported in the Journal of Clinical Oncology, Freedman et al found that the combination of neratinib and capecitabine was active against brain metastases in women with HER2-positive breast cancer. Modest activity of neratinib monotherapy had been found in previous...
SGO 2019: Post Hoc Exploratory Analyses From the ARIEL3 Trial in Recurrent Ovarian Cancer
Data from post hoc exploratory analyses from the phase III ARIEL3 clinical study of rucaparib in recurrent ovarian cancer was presented during oral plenary and poster sessions at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer. These analyses...
Intracranial Malignancy After Stereotactic Radiosurgery for Nonmalignant Conditions
In a retrospective cohort study reported in The Lancet Oncology, Douglas Kondziolka, MD, of NYU Langone Health System, and colleagues found that patients undergoing Gamma Knife stereotactic radiosurgery for nonmalignant neurosurgical conditions did not appear to be at long-term increased risk of...
SGO 2019: Dendritic Cell–Based Immunotherapy in Combination With Chemotherapy in Recurrent Ovarian Cancer
Results from a clinical trial presented by Cibula et al at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that a new immunotherapy treatment significantly prolongs survival in women with recurrent ovarian cancer when added to standard...
Docetaxel Plus Androgen-Deprivation Therapy After Primary Local Therapy in High-Risk Prostate Cancer
In a French phase III trial reported in JAMA Oncology, Stéphane Oudard, MD, PhD, of Hôpital Européen Georges Pompidou, and colleagues found that the addition of docetaxel to androgen-deprivation therapy (ADT) did not improve prostate-specific antigen (PSA) progression-free survival in men with...
Patient-Reported Outcomes With Enzalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
As reported by Bertrand Tombal, MD, of the Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, and colleagues in The Lancet Oncology, treatment with enzalutamide was associated with clinically meaningful delays in pain progression, symptom worsening, and deterioration in...
SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity
Findings from a recent clinical trial presented in a Scientific Plenary session at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer revealed that women with recurrent ovarian cancer who received niraparib as maintenance therapy experienced more time...
Use Technology and Appreciate the Importance of Partners
Most oncologists are comfortable treating lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients with cancer, according to a survey of 149 oncologists from 45 National Cancer Institute–designated Comprehensive Cancer Centers, but not as confident in their knowledge of the...
Knowing Gender Identity and Sexual Orientation of Patients Is a Vital Aspect of Medical Care
A survey of oncologists from National Cancer Institute (NCI)-designated Comprehensive Cancer Centers found that 95.3% of oncologists who responded are comfortable with treating lesbian, gay, and bisexual patients with cancer, and 82.5% are comfortable treating transgender patients with cancer.1...
Restarting My Life After Terminal Cancer
At the end of 2015, I was dying. I was just 50 years old and a wife and mother of 2 teenage boys. Twelve years earlier, I had been diagnosed with ductal carcinoma in situ in my left breast. Despite a modified radical mastectomy and removal of nearly all of the lymph nodes in my left underarm—which ...
Obesity, Examined and Explained
BOOKMARK Title: The Obesity Code: Unlocking the Secrets of Weight LossAuthor: Jason Fung, MDPublisher: Greystone BooksDate: March 2016Price: $18.95, paperback; 296 pages According to data from the National Cancer Institute (NCI), obesity plays a significant role in developing at least 12 different ...
SGO 2019: Brachytherapy Boost Added to EBRT and Chemotherapy in Advanced Cervical Cancer
A recent National Cancer Database study has shown the current standard of care for advanced cervical cancer—external-beam radiation and chemotherapy in combination with brachytherapy—provides significantly higher overall survival over chemoradiation alone. However, the addition of...
SGO 2019: HPV Vaccine Uptake in the Deep South
A study by Pierce et al presented at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that human papillomavirus (HPV) vaccination rates in Alabama are highest in counties with high incidence rates of HPV-related cancer (Abstract 13). ...
Florida Cancer Specialists Welcomes Nalini Hasija, MD
Florida Cancer Specialists & Research Institute have announced that medical oncologist/hematologist Nalini Hasija, MD, has joined the statewide practice, which encompasses a network of nearly 100 locations. Dr. Hasija will be seeing patients at the Tampa Cancer Center. Professional Training Dr. ...
Sweet Surrender
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
WebMD Recognizes Seven Cancer Innovators With Its Health Heroes Award
On January 15, 2019, WebMD, an online and print health-care resource for consumers, presented its 2018 Health Heroes Award in New York City to 7 people who are making a difference in oncology care. The honorees include Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology at Wake...
FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer
On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer. IMpower133 Approval was based on the IMpower133 study, a...
The Risks of Drug Approval Based on Shaky Evidence
Two recent publications in The New England Journal of Medicine (NEJM), and the resulting drug approval applications that have already been filed, lead to concern that the basis of medical practice on valid evidence may be corrupted. Each involves statistically shaky analysis leading to a striking...
Jeffrey Bluestone, PhD, Awarded Distinguished Lectureship
The American Association for Cancer Research (AACR) has awarded the 15th AACR–Irving Weinstein Foundation Distinguished Lectureship to Jeffrey Bluestone, PhD. The award was presented during the 2019 AACR Annual Meeting in Atlanta. Dr. Bluestone is President and Chief Executive Officer of the...
Johns Hopkins Greenberg Bladder Cancer Institute Awards Research Grants to Women’s Bladder Cancer Projects
The Johns Hopkins Greenberg Bladder Cancer Institute awarded research grants to four projects that focus on bladder cancer treatments in women and how biology could offer new targets for cancer therapy.The Institute awards grants of $25,000 to $50,000. David McConkey, PhD, Director of the...
ASCO President-Elect Howard A. Burris III, MD, FACP, FASCO, Gained Leadership Skills From His Experience at West Point
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Howard A. “Skip” Burris III, MD, FACP,...
